Medicines and Related Substances Control Amendment Act, 1997
Contents
South Africa's Medicines and Related Substances Control Amendment Act, 1997
Enactment
In an effort to combat the growing HIV/AIDS epidemic, the Government of South Africa enacted the Medicines and Related Substances Control Amendment Act in 1997.[1][2] The Act aimed to both reduce the cost of drugs and increase their availability.[2]
Challenge to the Law
In February 1998, the South African Pharmaceutical Manufactures Association and forty Multinational Corporations (MNC) brought a suit against the government of South Africa for its passage of the Medicines and Related Substances Control Amendment Act No. 90 of 1997, arguing that it violated the Agreement on Trade-Related Aspects of Intellectual Property Rights.[3] The intent of the Act was to reduce drug prices by allowing generic substitution of off-patent drugs, the parallel importation of on-patent drugs as well as price transparency.[3] In agreement with the suit, the United States (US) and European Communities (EC) threatened economic sanctions.[3] However, HIV/AIDS activists framed the debate successfully—e.g., demonstrators alleged that then United States presidential-candidate Al Gore was killing babies in Africa—and forced the US and EC to back off the South African government.[3] As a result of immense international pressure, the pharmaceutical companies dropped their case in April 2001.[3]
References
- ↑ [1], Medicines and Related Substances Control Amendment Act of 1997
- ↑ 2.0 2.1 Duane Nash, “South Africa's Medicines and Related Substances Control Amendment Act of 1997,” Berkeley Technology Law Journal 15 (2002): 485-504
- ↑ 3.0 3.1 3.2 3.3 3.4 Hoen, Ellen ’t, “TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and Beyond,” Chicago Journal of International Law 3, no. 1 (2002): 27–46
